European study reveals barriers to multinational clinical trials
2 Articles
2 Articles
European study reveals barriers to multinational clinical trials
A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials.
Researchers who want to start clinical studies on new treatments or medicines in EU countries often have to wait a long time. Due to complex and extensive regulations, it usually takes months before such studies can start. Researchers from UMC Utrecht and others point out that it can be done much faster, especially in times of crisis.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium